MedTrace Logo

Bone MicroArchitecture in Acromegaly

NCT03225040 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2021-07-13

No results posted yet for this study

Summary

The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH) receptor antagonist for at least 1 year and with normal insulin-like growth factor-1 (IGF-1) levels. This study aims to describe the bone architecture and associated biochemical indices of bone turnover and metabolism in patients with active acromegaly and how these are altered with treatment of the disease.

Conditions

Interventions

DRUG

Pegvisomant

Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.

Sponsors & Collaborators

Principal Investigators

  • Pamela Freda, MD · Columbia University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-03
Primary Completion
2019-12-21
Completion
2019-12-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03225040 on ClinicalTrials.gov